fbpx

QQQ
+ 2.31
364.32
+ 0.63%
BTC/USD
-741.49
60930.93
-1.2%
DIA
+ 3.70
345.43
+ 1.06%
SPY
+ 3.26
439.24
+ 0.74%
TLT
-0.85
146.73
-0.58%
GLD
-2.66
170.66
-1.58%

Analyst Ratings For Dicerna Pharmaceuticals

August 6, 2021 12:24 pm
Share to Linkedin Share to Twitter Share to Facebook Share to Print License More

Dicerna Pharmaceuticals (NASDAQ:DRNA) has observed the following analyst ratings within the last quarter:

Last 30 Days 1 Month Ago 2 Months Ago 3 Months Ago
Bullish 2 0 1 0
Somewhat Bullish 2 0 0 0
Indifferent 1 0 0 0
Somewhat Bearish 0 0 0 0
Bearish 0 0 0 0

In the last 3 months, 7 analysts have offered 12-month price targets for Dicerna Pharmaceuticals. The company has an average price target of $39.0 with a high of $48.00 and a low of $30.00.

price target chart

This current average has decreased by 10.96% from the previous average price target of $43.8.

Analyst Ratings: What Are They?

Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish “analyst ratings” for stocks. Analysts typically rate each stock once per quarter.

Analysts also give out recommendations like “buy”, “sell”, “hold”, or similar verbage for each stock based on their overall evaluations of the corres ponding company. A “buy” indicates that an analyst is optimistic about a stock’s short-term or mid-term growth, recommending traders to purchase the stock. Contrastingly, a “sell” means that an analyst believes the stock will trend downwards in that same time frame. A “hold” suggests that investors should not buy more of or sell any of the specified stock due to that analyst’s prediction of stagnation.

Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.

For the latest in financial news, exclusive stories, memes follow Benzinga on Twitter, Facebook & Instagram. For the best interviews, stock market talk & videos, subscribe to Benzinga Podcasts and our YouTube channel.

Posted-In:

Analyst Ratings

Related Articles

Where Dicerna Pharmaceuticals Stands With Analysts

Analysts have provided the following ratings for Dicerna Pharmaceuticals (NASDAQ:DRNA) within the last quarter: Last 30 Days 1 Month Ago read more

What 10 Analyst Ratings Have To Say About Dicerna Pharmaceuticals

Analysts have provided the following ratings for Dicerna Pharmaceuticals (NASDAQ:DRNA) within the last quarter: Last 30 Days 1 Month Ago 2 Months Ago read more

Benzinga's Top Ratings Upgrades, Downgrades For August 11, 2021

  read more
10 Biggest Price Target Changes For Wednesday

10 Biggest Price Target Changes For Wednesday

Rosenblatt raised Coinbase Global, Inc. (NASDAQ: COIN) price target from $400 to $420. Coinbase shares rose 2.2% to $275.51 in pre-market trading. read more